PrognomiQ: Brian Koh, Bruce Wilcox
PrognomiQ has appointed Brian Koh as chief medical officer, a role in which he will be responsible for developing and executing the multiomics company's clinical development and medical strategy. Koh previously served as head of translational sciences and clinical development at Vividion Therapeutics. Prior to that, he held positions of increasing responsibility at both Gilead Sciences and Kite Pharma. He received his undergraduate training at Harvard, and received an MD, MS, and MPhil from Yale University. He also completed a postdoc in clinical pharmacology at Mayo Clinic-Rochester while holding a triple academic appointment as an instructor in the departments of medicine, oncology, and pharmacology.
PrognomiQ said that it has also promoted Bruce Wilcox, one of the company's founding leaders, to the position of chief technology officer. He was previously VP of proteomics.